Royalty Pharma plc (RPRX) stock
RPRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 8/3050% above fair value
$68.67−0.01 (-0.01%)
Close on Nov 18, 2026Market cap $39.49BP/E 39.0Yield –
Royalty Pharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Royalty Pharma's operating income for the twelve months ending Jun 30, 2026 was $1.51B, down 17.9% year over year. For fiscal 2025 it was $1.56B, up 20.7% from the year before. The highest annual figure on record is $2.62B in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.56B | +20.7% |
| FY2024 | Dec 31, 2024 | $1.29B | -13.4% |
| FY2023 | Dec 31, 2023 | $1.49B | +385.9% |
| FY2022 | Dec 31, 2022 | $307.07M | -78.5% |
| FY2021 | Dec 31, 2021 | $1.43B | -10.3% |
| FY2020 | Dec 31, 2020 | $1.60B | -39.2% |
| FY2019 | Dec 31, 2019 | $2.62B | +92.3% |
| FY2018 | Dec 31, 2018 | $1.36B | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $133.12M | -36.5% |
| Q1 FY2026 | Mar 31, 2026 | $563.04M | +5.4% |
| Q4 FY2025 | Dec 31, 2025 | $388.38M | +7.4% |
| Q3 FY2025 | Sep 30, 2025 | $427.16M | -41.9% |
| Q2 FY2025 | Jun 30, 2025 | $209.80M | -22.2% |
| Q1 FY2025 | Mar 31, 2025 | $534.18M | – |
| Q4 FY2024 | Dec 31, 2024 | $361.51M | -41.0% |
| Q3 FY2024 | Sep 30, 2024 | $735.07M | +385.4% |
| Q2 FY2024 | Jun 30, 2024 | $269.63M | +8.4% |
| Q1 FY2024 | Mar 31, 2024 | -$73.77M | -115.4% |
| Q4 FY2023 | Dec 31, 2023 | $612.90M | – |
| Q3 FY2023 | Sep 30, 2023 | $151.44M | -21.2% |
| Q2 FY2023 | Jun 30, 2023 | $248.84M | -34.1% |
| Q1 FY2023 | Mar 31, 2023 | $478.97M | +118.0% |
| Q4 FY2022 | Dec 31, 2022 | -$482.66M | -414.6% |
| Q3 FY2022 | Sep 30, 2022 | $192.21M | -36.6% |
| Q2 FY2022 | Jun 30, 2022 | $377.79M | -49.3% |
| Q1 FY2022 | Mar 31, 2022 | $219.72M | -4.2% |
| Q4 FY2021 | Dec 31, 2021 | $153.42M | -51.1% |
| Q3 FY2021 | Sep 30, 2021 | $303.05M | -40.6% |
| Q2 FY2021 | Jun 30, 2021 | $744.95M | +82.0% |
| Q1 FY2021 | Mar 31, 2021 | $229.30M | -36.6% |
| Q4 FY2020 | Dec 31, 2020 | $314.06M | -76.4% |
| Q3 FY2020 | Sep 30, 2020 | $510.57M | -4.1% |
| Q2 FY2020 | Jun 30, 2020 | $409.35M | +24.9% |
| Q1 FY2020 | Mar 31, 2020 | $361.43M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.33B | – |
| Q3 FY2019 | Sep 30, 2019 | $532.50M | – |
| Q2 FY2019 | Jun 30, 2019 | $327.86M | – |
See a number that looks wrong?